RL
UTHR icon

Ruffer LLP’s United Therapeutics UTHR Stock Holding History

Ruffer LLP’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-48,545
Closed -$20.3M – 183
2025
Q3 		$20.3M Buy
48,545
+37,782
+351% +$12.7M 1.13% 27
2025
Q2 		$3.09M Sell
10,763
-3,611
-25% -$1.08M 0.14% 77
2025
Q1 		$4.43M Buy
14,374
+2,925
+26% +$1M 0.17% 66
2024
Q4 		$4.04M Buy
+11,449
New +$4.21M 0.15% 69

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Ruffer LLP's UTHR Position: Q4 2025 in Review

Ruffer LLP sold out of United Therapeutics (UTHR) in Q4 2025, closing a stake of 48,545 shares — an estimated $20.3M sold.

Ruffer LLP first reported a position in UTHR in Q4 2024 and held it in 4 quarters. The position peaked at $20.3M in Q3 2025. 838 funds tracked by Wall St. Rank hold UTHR as of Q4 2025.

  • Ruffer LLP reported no remaining United Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Ruffer LLP sold 48,545 United Therapeutics shares in Q4 2025, an estimated $20.3M.
  • Ruffer LLP first reported a position in United Therapeutics in Q4 2024 and held it in 4 quarters.
  • Ruffer LLP's United Therapeutics position peaked at $20.3M in Q3 2025.
  • 838 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2025.

Based on Ruffer LLP's 13F filing for Q4 2025, filed 28 Jan 2026.